Sherpa Healthcare Partners

AiLian Health is a digital healthcare service platform. Based on the medical supply chain and medical big data,

New Vision Medical is an IT infrastructure service provider that offers clinical trial-related digital platforms and services.

Kunwei Technology manufactures high-precision force sensors (six-axis force sensors) as well as force control systems. It is involved in the research and development, manufacturing, sales, and technological promotion of intelligent force sensors, as well as the development of force sensor products for the robot and other intelligent equipment industries. It provides force measurement systems as well as goods connected to measurement and other industries.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.

Agile Medical, a surgical robot company, focuses on research, development, and industrialization of intelligent surgical products. Agile Medical's technology innovation platform covers mechanics, electronics, optics, computing, and software.

Brise Pharma is a biopharmaceutical company dedicated to developing innovative drugs aimed at treating pain. The company focuses on creating highly differentiated analgesic treatments for various debilitating pain conditions, particularly targeting migraine, neuropathic, and musculoskeletal pain. By addressing significant unmet needs in pain management, Brise Pharma aims to enable healthcare providers to offer safe, effective, and accessible pain relief solutions for patients worldwide who suffer from poorly managed pain conditions.

Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.

ZWI Therapeutics is a biotechnology company focused on enhancing the efficacy and safety of protein therapeutics. The company is developing an advanced polymer designed to reduce immunogenicity and improve pharmacokinetics, facilitating the creation of nanoparticles and hydrogels for therapeutic use. Utilizing machine learning, ZWI Therapeutics aims to identify and develop immunotherapies that minimize immune responses, paving the way for new treatments for cancer, autoimmune diseases, and various other conditions. Through its innovative approach, ZWI Therapeutics seeks to provide patients with effective and safe treatment options.

Astra is a rocket launch startup that provides satellite delivery and launch services. It offers online reservations for payload deliveries to both sun-synchronous and low-inclination orbits. Astra also offers dedicated launch services of 50kg-150kg payloads to 500km SSO reference orbit in 2020 and 2021. The company focuses on providing cost-effective and frequent access to space for small satellite payloads. Astra aims to simplify the process of launching payloads into space by developing lightweight and agile rockets that can be found from various locations. Astra has been actively conducting launch campaigns to demonstrate its capabilities and improve its technology. As with any ambitious space venture, Astra has faced its fair share of challenges and setbacks in developing and launching rockets.

Lifeshield Medical focuses on life support systems. The current products include a new generation of in vivo interventional cardiac support systems, extracorporeal carbon dioxide removal systems (ECCO2R) for the treatment of severe COPD and ECMO extracorporeal membrane oxygenation systems. The company is actively cooperating with domestic clinicians and continues to develop and industrialize several innovative life support system products and solutions such as heart, brain, lung, liver, and kidney to meet the clinical needs of the Chinese and EU markets and serve more patients.

GRIT Biotechnology is a research and development company based in Shanghai, China, focusing on tumor infiltration lymphocytes (TIL) immunotherapy for the treatment of solid tumors. Founded in 2019, the company is dedicated to advancing the field of immunotherapy with the aim of enhancing the effectiveness of tumor treatments. By leveraging innovative approaches in TIL technology, GRIT Biotechnology seeks to provide new therapeutic options for patients battling solid tumors.

Leadsynbio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzyme engineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.

New Vision Medical is an IT infrastructure service provider that offers clinical trial-related digital platforms and services.

Hongyun Biotech is a biotech company that promotes therapeutic innovation based on structural pharmacology.

Danatlas is a pharmaceutical company that develops drugs designed for oncology treatment. It also provides drug research and development in the fields of cancer, inflammation, blood, and metabolic diseases.

BlissBio is a biopharmaceutical company dedicated to the development of innovative therapies for cancer treatment. The company specializes in tumor targeting and immunotherapy, focusing on the creation of antibody-drug conjugates and site-specific conjugate technologies. With a robust pipeline of products, BlissBio possesses independent intellectual property rights that support the advancement and commercialization of its anti-tumor therapies, aiming to provide effective solutions for patients battling cancer.

Huihe Healthcare, founded in 2019 and based in Shanghai, China, focuses on the development and research of medical devices aimed at treating structural heart disease. The company is dedicated to creating innovative solutions for heart conditions, including a tricuspid valve repair system. By concentrating on intervention medical devices, Huihe Healthcare seeks to provide effective treatments for patients suffering from various heart diseases.

Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.

Neukio Biotherapeutics specializes in developing allogenic immune cell therapies for cancer treatment. The company is dedicated to the research, development, and industrialization of immune cell drugs, particularly through its innovative iPSC-CAR-NK technology. By combining in-house innovation with collaborations with leading partners, Neukio aims to create effective therapeutic solutions for cancer patients globally. Through its efforts, the company seeks to advance the commercialization of these novel treatments, ensuring they are accessible to oncology providers and ultimately improving patient outcomes.

ClinChoice Kunling was established in Tianjin inSince its establishment, through its own organic growth and strategic mergers and acquisitions, ClinChoice has more than 3,000 clinical R&D professionals around the world, located in hot cities and regions of domestic and foreign pharmaceutical R&D, and has developed into a local clinical CRO enterprise model supporting innovative drug device R&D. . The company adheres to the connotation of "Kunxing Zhiyuan · Ling creates the future", which means to become an ideal partner for the clinical research and development of innovative pharmaceutical devices.

Developer of edible microbial synthetic protein food intended to provide new form of protein sources. The company focuses on the research, development and industrialization of new microbial proteins and biosynthetic proteins, enabling clients with safe, nutritious and delicious microbial substitute protein artificial food, while lowering carbon emissions.

Yuanyin Bio is a biotechnology company focuses on the research and application of circular RNA technology in the field of innovative drugs and therapies, builds a robust pipeline of preventive and therapeutic new drugs, and is dedicated to addressing clinically unmet disease needs. They serve in the field of innovative drugs and therapies. It establishes a pipeline of preventive and therapeutic new drugs and is committed to solving clinically unmet disease needs.

Raykol is a national high-tech enterprise in China specializing in automated and intelligent laboratory solutions aimed at enhancing the efficiency of the inspection and testing industry. The company focuses on three primary sectors: food safety, environmental protection, and life sciences. It offers a comprehensive range of services including R&D, production, sales, and third-party testing. Raykol's expertise stems from its development of automated stand-alone modules, machine vision, and motion control technology, enabling the creation of fully integrated workstations for laboratory automation. Additionally, the company operates a service and training center that provides after-sales support, training, demonstration, analysis outsourcing, method development, and project cooperation, ensuring customers receive complete one-stop solution services.

Starna Therapeutics is focused on developing innovative drugs that utilize RNA technology at their core. The company possesses a proprietary RNA and organ-selective delivery technology platform, which underpins its extensive research and development pipeline. This pipeline addresses unmet clinical needs in various areas, including vaccines for infectious diseases, tumor immunology, and metabolic disorders. By leveraging its independent intellectual property rights, Starna Therapeutics aims to advance the field of RNA-based therapeutics and contribute to significant advancements in healthcare.

HuidaGene Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2018. The company specializes in the research and development of gene therapies for single-gene disorders and is expanding its focus to neurodegenerative diseases and vision disorders. HuidaGene employs its proprietary CRISPR-based and AI-driven HG-PRECISE platform to create potentially curative therapies. Among its clinical programs, HuidaGene is advancing HG004 for RPE65-associated retinal disease, HG202 for neovascular age-related macular degeneration, HG204 for MECP2 duplication syndrome, and HG302 for Duchenne muscular dystrophy. Several of these therapies have received orphan drug designations and rare pediatric disease designations from regulatory authorities. In addition to its clinical initiatives, the company is exploring preclinical programs, including HG303 for amyotrophic lateral sclerosis and a CRISPR RNA-editing therapy for Alzheimer’s disease.

Cataya Bio (Shanghai) Co., Ltd. is focused on developing synthetic biological products for diverse industries through its advanced engineering biology platform and biomanufacturing capabilities. The company engineers microbes and creates clean fermentation processes to produce high-purity products sustainably and cost-effectively. By leveraging synthetic biology technology, Cataya Bio enables clients to obtain natural and sustainable raw materials, contributing to a shift away from petroleum-based resources. The company's efforts address critical global challenges such as environmental preservation, carbon emissions, and climate change.

Shenji Bio focuses on the research and development of fundamental raw materials such as nucleosides, nucleotides, diagnostic antigens, and antibodies. As a development direction, Shenji Bio provides cost-effective products and addresses clinical unmet needs. It has gradually entered the upstream core raw material fields of IVD, mRNA, CGT, and other industries, and has established a high-quality key common technology platform to provide overall solutions for the life science field's development.

UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders.

UniXell Biotechnology is a developer of cell therapies utilizing human pluripotent stem cell technology. The company focuses on addressing unmet medical needs in neurodegenerative diseases, rare diseases, and tumors. UniXell has established multiple key technology platforms, including reprogramming technology, stem cell differentiation, SISBAR pedigree tracing technology, and high-precision gene editing. These innovations enable the development of effective treatment solutions aimed at improving the lives of patients suffering from complex medical conditions. The company's proprietary intellectual property encompasses various aspects of stem cell preparation, cultivation, differentiation, and gene editing, positioning it as a leader in the advancement of cellular therapies.

Leadsynbio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzyme engineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.

Leadsynbio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzyme engineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.

MindRank is an artificial intelligence (AI)-driven drug discovery company focused on streamlining the drug development process. Utilizing its proprietary AI platforms, including PharmKG, Molecule Dance, and Molecule Pro, the company aims to expedite the creation of small molecule medicines that offer unique benefits and improved clinical outcomes. MindRank's technology efficiently recommends cost-effective synthesis routes for various compounds and supports drug design, enabling clients to develop effective pharmaceuticals more quickly and efficiently. Through its innovative approach, MindRank seeks to transform the landscape of drug discovery.

Starna Therapeutics is focused on developing innovative drugs that utilize RNA technology at their core. The company possesses a proprietary RNA and organ-selective delivery technology platform, which underpins its extensive research and development pipeline. This pipeline addresses unmet clinical needs in various areas, including vaccines for infectious diseases, tumor immunology, and metabolic disorders. By leveraging its independent intellectual property rights, Starna Therapeutics aims to advance the field of RNA-based therapeutics and contribute to significant advancements in healthcare.

BAKX Therapeutics is a company focused on developing innovative cancer treatments. It specializes in creating orally active therapeutics that target the mitochondrial apoptosis pathway, which plays a crucial role in cell death and cancer progression. By leveraging insights into the dynamic protein structures involved in this pathway, along with advanced structure-based drug design and computational simulations, BAKX aims to enhance the effectiveness and longevity of cancer therapies. The company's approach seeks to provide medical professionals with improved treatment options for cancer patients.

Sepax Technologies is a biotechnology firm specializing in chromatography products aimed at the separation and purification of pharmaceuticals and biologics. The company provides a diverse range of offerings, including liquid chromatography columns, bulk resins, and systems that cater to various modalities such as size exclusion chromatography, ion exchange, hydrophobic interaction chromatography, affinity chromatography, and reversed-phase chromatography. These products are designed to assist biological researchers and scientists in achieving high-resolution, high-efficiency, and high-recovery separations of proteins, oligonucleotides, peptides, and other biomolecules. Additionally, Sepax Technologies offers method development services to further support its clients in their research endeavors.

Fuse Biotherapeutics is a biotechnology company focused on developing innovative immune-modulating therapeutics for cancer patients. Established in 2021 and based in Los Angeles, the company employs a rational approach to its therapeutic development, integrating multiple steps of the immune response. This approach aims to harness potent immune responses to target cancer effectively while preserving the natural mechanisms that protect healthy tissues. By prioritizing safety alongside efficacy, Fuse Biotherapeutics seeks to create new treatment options that offer advantages over existing therapies in the cancer treatment landscape.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

Jianhai Technology is an AI whole-course management platform that provides users with post-hospital & post-diagnosis management services.

Wuxi Biortus Biosciences Co. Ltd. is a contract research organization based in Jiangyin, China, specializing in research and development services that support drug discovery. Founded in 2009, the company offers a range of services, including recombinant protein production, in vitro assays and screening, medicinal chemistry, structural biology, and target validation. Wuxi Biortus Biosciences is recognized for its commitment to quality and innovation, having established five advanced research platforms that enhance its capabilities in drug development. The company’s R&D team has developed various innovative techniques, some of which have been patented, further solidifying its role in the biotechnology sector. It operates as a subsidiary of Jiangsu Shuangliang Group Company Ltd.

Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.

Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.

Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.

CashBackApp is a financial technology company that focuses on enhancing customer loyalty for fast-moving consumer goods (FMCG) companies. The platform enables consumers to earn cashback through M-Pesa on their everyday purchases from participating brands and retailers. By partnering with FMCG companies, CashBackApp allows these businesses to quickly implement and manage promotional offers at scale, effectively incentivizing shoppers to purchase products featured on the app. This approach not only fosters customer loyalty but also drives sales through mobile channels, providing a cost-effective solution for retailers looking to engage consumers.

Krinwave Technology specializes in manufacturing ultrasound imaging equipment for medical use. Its proprietary kOS imaging platform stands out by offering ultra-high penetration and deep resolution, generating highly detailed images. The company focuses on delivering high-performance solutions for whole-body, cardiac, and obstetric/gynecological applications, aiding doctors in early disease detection and diagnosis.

Bota Biosciences is a global industrial biotechnology company based in Hangzhou, China, founded in 2019. The company specializes in synthetic bioengineering technology for bio-manufacturing, focusing on developing efficient, eco-friendly, and cost-effective solutions. Bota Biosciences has created an integrative bioengineering platform that connects biological design to scale-up manufacturing, facilitating the transition to sustainable living. It operates its own pilot plant and manufacturing facility, which enhances its capacity to offer scalable industrial solutions and market-ready products across various sectors, including nutrition, food, personal care, and animal health. With a dynamic and multidisciplinary team, Bota Biosciences aims to channel biotechnology innovations for a global impact. The company has successfully raised substantial funding, exceeding $145 million, with investments from several prominent strategic and financial backers.

Neukio Biotherapeutics specializes in developing allogenic immune cell therapies for cancer treatment. The company is dedicated to the research, development, and industrialization of immune cell drugs, particularly through its innovative iPSC-CAR-NK technology. By combining in-house innovation with collaborations with leading partners, Neukio aims to create effective therapeutic solutions for cancer patients globally. Through its efforts, the company seeks to advance the commercialization of these novel treatments, ensuring they are accessible to oncology providers and ultimately improving patient outcomes.

Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.

Hongyun Biotech is a biotech company that promotes therapeutic innovation based on structural pharmacology.

Jyss Bio is a developer of disposable bioreactors and peripheral equipment.

MAXVAX is focused on the development and commercialization of innovative vaccines, specifically targeting viral diseases such as rotavirus, shingles, and herpes. The company's technology is designed to enhance treatment options within the biotechnology industry, enabling healthcare professionals to offer improved solutions for patients suffering from these infections. By concentrating on effective vaccine development, MAXVAX aims to contribute significantly to the healthcare sector and improve patient outcomes.

PAQ Therapeutics is a biotechnology company focused on restoring health and curing diseases by harnessing autophagy, the body's natural process for cellular degradation. The company develops a novel class of small-molecule degraders using autophagosome-tethering compound technology. This innovative approach allows these compounds to bind a diverse array of substrates to the autophagy pathway, enabling healthcare providers to create effective treatments for serious diseases where traditional therapeutic options are often limited. Through its research and development efforts, PAQ Therapeutics aims to provide new solutions for patients in need of advanced medical therapies.

HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.

XISOFT is a professional manufacturer specializing in informatization and data services within health economic management. The company develops an enterprise resource planning (ERP) platform tailored for hospitals, providing comprehensive management and monitoring capabilities across various functions, including finance, supply chain, human resources, and diagnosis-related groups. By leveraging technology, XISOFT aims to support medical institutions in streamlining operations and enhancing efficiency. Its platform enables effective business integration and refined management, addressing key areas such as intelligent finance, material assets, internal control, and event management. Through its innovative solutions, XISOFT assists healthcare providers in realizing their strategic objectives and improving overall operational effectiveness.

MindRank is an artificial intelligence (AI)-driven drug discovery company focused on streamlining the drug development process. Utilizing its proprietary AI platforms, including PharmKG, Molecule Dance, and Molecule Pro, the company aims to expedite the creation of small molecule medicines that offer unique benefits and improved clinical outcomes. MindRank's technology efficiently recommends cost-effective synthesis routes for various compounds and supports drug design, enabling clients to develop effective pharmaceuticals more quickly and efficiently. Through its innovative approach, MindRank seeks to transform the landscape of drug discovery.

Appia Bio is a biotechnology company dedicated to the research and development of allogeneic cell therapies that can be readily available for patients. The company focuses on creating engineered cell therapies for various medical conditions using its innovative ACUA technology platform. This platform utilizes the biology of lymphocyte development along with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to produce CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes derived from hematopoietic stem cells. By maturing and scaling healthy stem cells into these therapies, Appia Bio aims to provide safe and targeted cancer treatments, thereby enhancing accessibility to off-the-shelf cell therapies for physicians and patients alike.

Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.

EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.

Brattea is a medical device research and development company specializing in renal denervation products aimed at treating conditions such as hypertension, cancer pain, and diabetes. The company develops interventional devices, including renal artery ablation catheters and radiofrequency ablation equipment, as well as medical mapping systems. These products are designed to address a range of health issues, including refractory hypertension, obstructive sleep apnea, kidney disease, and heart failure. Brattea is committed to providing reliable medical solutions that enhance patient care and improve health outcomes.

Jianhai Technology is an AI whole-course management platform that provides users with post-hospital & post-diagnosis management services.

EpimAb Biotherapeutics is a biopharmaceutical company based in Shanghai, China, focused on the research and development of novel bispecific antibody therapeutics. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, the company creates bispecific molecules that possess antibody-like properties. This innovative approach aims to address the challenges associated with developing effective bi-specific antibodies, which are engineered from two different monoclonal antibodies to combine their therapeutic features into a single entity. These bispecific antibodies hold promise for treating various life-threatening conditions, particularly in immuno-oncology, by offering new therapeutic options. Despite the potential benefits of bi-specific antibodies, many candidates face hurdles in development due to issues related to their binding properties, pharmacokinetics, and production costs. EpimAb Biotherapeutics is positioned to contribute to the growing need for advanced bi-specific therapeutics in the pharmaceutical industry.

Visen Pharmaceuticals is a biopharmaceutical company that specializes in the development and commercialization of innovative therapies for endocrine diseases. The company is dedicated to addressing significant unmet medical needs in this field, particularly within the Chinese market, and aims to provide both first-in-class and best-in-class treatment solutions for patients of all ages, including those with rare endocrine conditions. With a commitment to patient-centric care, Visen strives to improve treatment outcomes and quality of life for individuals affected by these diseases. The company is backed by a team of experienced professionals with extensive backgrounds in the pharmaceutical industry and operates offices in major Chinese cities such as Shanghai, Beijing, Hong Kong, and Taipei. To further enhance its research, development, and manufacturing capabilities, Visen has established a Greater China research and development site in Suzhou, aiming to deliver advanced treatment options to Chinese patients more effectively.

CotheraBio develops innovative cancer therapies with a focus on translational oncology. It has developed its proprietary i-CR® technology platform, which is a powerful method for providing individualized drug screening and new drug development. The platform combines a high content screening system with the conditional reprogramming of primary cultured tumor cells, which enables the efficient and undifferentiated expansion of primary patient-derived tumor cells in vitro, while also preserving the tumor’s heterogeneity.

Shanhu Health focuses on the development of clinical application software within the realm of digital medicine. The company creates computerized systems aimed at enhancing clinical research, including interactive response technology, electronic data capture, and clinical trial management systems, all utilizing cloud technology. Additionally, Shanhu Health offers consultancy services that support risk-based monitoring and the implementation of clinical trial systems, thereby facilitating more efficient drug development processes.

Vazyme Biotech Co., Ltd. is a biotechnology company based in Nanjing, China, founded in 2012. The company specializes in the development and production of enzymes and antibodies, with applications across various fields including clinical diagnosis, molecular diagnostics, high-throughput sequencing, and life science research. Vazyme Biotech is recognized for its advanced research and development capabilities and employs cutting-edge technology to innovate within the biotechnology sector. Its strategic location in the National Economic and Technological Development Zone of Nanjing allows the company to leverage regional resources and expertise, positioning it to play a significant role in the national biotechnology landscape.

Jianhai Technology is an AI whole-course management platform that provides users with post-hospital & post-diagnosis management services.

Bota Biosciences is a global industrial biotechnology company based in Hangzhou, China, founded in 2019. The company specializes in synthetic bioengineering technology for bio-manufacturing, focusing on developing efficient, eco-friendly, and cost-effective solutions. Bota Biosciences has created an integrative bioengineering platform that connects biological design to scale-up manufacturing, facilitating the transition to sustainable living. It operates its own pilot plant and manufacturing facility, which enhances its capacity to offer scalable industrial solutions and market-ready products across various sectors, including nutrition, food, personal care, and animal health. With a dynamic and multidisciplinary team, Bota Biosciences aims to channel biotechnology innovations for a global impact. The company has successfully raised substantial funding, exceeding $145 million, with investments from several prominent strategic and financial backers.

Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.

Hongyun Biotech is a biotech company that promotes therapeutic innovation based on structural pharmacology.

Belief Biomed brings the latest research achievements in precision medicine in Triangle area into production and promotes international collaboration by connecting established investors from China to explore the vast opportunity of North Carolina.

Nanovision Technology, based in the Zhongguancun Yongfeng high-tech industrial base with an additional subsidiary in Chengdu, specializes in high-speed and high-precision radiology imaging. The company focuses on the development of static CT, X-ray CMOS detectors, and X-ray imaging software. Notably, Nanovision created China's first self-developed CMOS flat panel detector, known as the Merak series. Its products are applicable in various sectors, including medical, industrial, and security, offering advanced technological support both domestically and internationally. With a significant research and development foundation, Nanovision is positioned as a key player in the radiation imaging industry.

Shanghai Kechow Pharma, Inc. is a biopharmaceutical company established in 2014 and headquartered in Shanghai, China. The company specializes in the discovery of targeted small molecule drugs, aiming to develop innovative therapies that improve upon existing treatments. KeChow Pharma collaborates with various partners to co-develop its drug candidates, emphasizing a commitment to advancing healthcare through novel therapeutic solutions.

HuidaGene Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2018. The company specializes in the research and development of gene therapies for single-gene disorders and is expanding its focus to neurodegenerative diseases and vision disorders. HuidaGene employs its proprietary CRISPR-based and AI-driven HG-PRECISE platform to create potentially curative therapies. Among its clinical programs, HuidaGene is advancing HG004 for RPE65-associated retinal disease, HG202 for neovascular age-related macular degeneration, HG204 for MECP2 duplication syndrome, and HG302 for Duchenne muscular dystrophy. Several of these therapies have received orphan drug designations and rare pediatric disease designations from regulatory authorities. In addition to its clinical initiatives, the company is exploring preclinical programs, including HG303 for amyotrophic lateral sclerosis and a CRISPR RNA-editing therapy for Alzheimer’s disease.

Guoke Hengtai (Beijing) Medical Technology Co., Ltd., established in February 2013, is a company based in the Yizhuang Economic and Technological Development Zone of Beijing. It operates under the umbrella of Oriental Science and Technology Holding Group Co., Ltd., a subsidiary of the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. The company specializes in the distribution and direct sales of medical devices, offering a range of professional services, including warehousing logistics, distribution channel management, and hospital SPD operation management. Since its inception, Guoke Hengtai has experienced significant growth, achieving a compound annual growth rate exceeding 50% over four years and embarking on an initial public offering journey in 2017.

Jianhai Technology is an AI whole-course management platform that provides users with post-hospital & post-diagnosis management services.

Hangzhou Joinhealth Technology Co., Ltd. specializes in developing software solutions for medical follow-up and post-hospital management. Founded in 2015 and headquartered in Hangzhou, China, the company offers a range of products including systems for hospital follow-up, VIP customer management, chronic disease management, and maternal and child health. Joinhealth Technology integrates artificial intelligence and advanced technologies like the Internet and Internet of Things to enhance patient management. By shifting the focus from disease treatment to comprehensive disease management, the company facilitates intelligent management of patients throughout their healthcare journey, from hospital care to home and potential re-admission.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

EpimAb Biotherapeutics is a biopharmaceutical company based in Shanghai, China, focused on the research and development of novel bispecific antibody therapeutics. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, the company creates bispecific molecules that possess antibody-like properties. This innovative approach aims to address the challenges associated with developing effective bi-specific antibodies, which are engineered from two different monoclonal antibodies to combine their therapeutic features into a single entity. These bispecific antibodies hold promise for treating various life-threatening conditions, particularly in immuno-oncology, by offering new therapeutic options. Despite the potential benefits of bi-specific antibodies, many candidates face hurdles in development due to issues related to their binding properties, pharmacokinetics, and production costs. EpimAb Biotherapeutics is positioned to contribute to the growing need for advanced bi-specific therapeutics in the pharmaceutical industry.

New Horizon Health is a biotechnology company based in Hangzhou, China, with an additional office in Beijing, specializing in the development of innovative technologies for early cancer detection and screening. Founded in 2015, the company primarily focuses on gastrointestinal cancers, offering products such as the ColoClear and Pupu Tube, which utilize fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. These products enable users to conduct in-home tests, allowing for the early detection of colon cancer and precancerous lesions that may not be identified through traditional blood tests. New Horizon Health aims to reduce cancer morbidity and mortality rates by promoting accessible and efficient health services, leveraging big data and artificial intelligence in its screening technologies. The company's commitment to early cancer screening reflects its mission to enhance public health by facilitating widespread access to vital diagnostic tools.

Leto Laboratories focuses on research and development in the field of protein re-engineering, aiming to address gaps in the treatment of cancer and rare diseases. The company employs advanced technologies, including high-throughput protein re-screening, purification, and drug formulation development platforms. By leveraging these innovative approaches, Leto Laboratories strives to create more effective protein-based therapies, enhancing treatment options for patients. The diverse research team works collaboratively to advance the company's mission of improving healthcare outcomes through specialized protein technology.

Yosemite Clinic is a multidisciplinary medical center located in Central Pudong, Shanghai, offering a wide range of walk-in services in a modern and well-equipped environment. The clinic provides specialties including family medicine, internal medicine, gynecology, pediatrics, rehabilitation, sports medicine, dentistry, ophthalmology, dermatology, and medical cosmetology. It is particularly noted for its focus on Minimally Invasive Surgery and Ambulatory Surgery. The facility is equipped with advanced medical imaging technology, including CT, X-ray, and ultrasound, alongside a fully operational laboratory and pharmacy. The clinic's diverse team of healthcare professionals hails from both China and around the world, allowing them to offer services in multiple languages such as English, Japanese, Malay, Mandarin Chinese, and Cantonese, ensuring comprehensive care for a diverse patient population.

ImmunoChina Pharmaceuticals manufactures medical products. The Company produces cell injections, cell therapy drugs, and other products. ImmunoChina Pharmaceuticals also provides medical technology development, medical research, medical trial development, and other services.

Hexaell Biotechnology Co., Ltd is a start-up specializing in stem cell technology and artificial organs, focusing on innovative solutions for severe liver diseases. The company has licensed advanced technologies for developing bio-artificial livers that aim to replace human liver function and treat liver failure. Hexaell's research is based on findings published in prominent scientific journals, and it has conducted pilot clinical studies involving six liver failure patients at leading hepatopathy centers in China. By employing cell differentiation and production techniques, Hexaell is committed to providing effective treatment options for those suffering from liver conditions.

Hongyun Biotech is a biotech company that promotes therapeutic innovation based on structural pharmacology.

Wuxi Biologics is a leading global contract development and manufacturing organization (CDMO) that specializes in biologics. Established in 2014 as a result of the reorganization of WuXi PharmaTech, the company offers comprehensive solutions that support organizations in the discovery, development, and manufacturing of biologic drugs, from initial concept to commercial production. With a significant revenue of CNY 17 billion, a considerable portion of its income, approximately 47.4%, is derived from North America as of 2023. Wuxi Biologics employs a strategy that focuses on following and winning drug molecules while utilizing a dual-sourcing approach to deliver both drug products and large-scale drug substance manufacturing services. The company plays a crucial role in facilitating the development of innovative biological treatments for various diseases on a global scale.

Wag is a mobile application used to instantly find trusted and certified dog walkers. You’ll receive a push notification when the walk starts, followed by real-time GPS tracking of the walk. Once the walk is complete, you’ll receive a report card with a photo, notes, the distance traveled, and a pee/poop report.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.

PAQ Therapeutics is a biotechnology company focused on restoring health and curing diseases by harnessing autophagy, the body's natural process for cellular degradation. The company develops a novel class of small-molecule degraders using autophagosome-tethering compound technology. This innovative approach allows these compounds to bind a diverse array of substrates to the autophagy pathway, enabling healthcare providers to create effective treatments for serious diseases where traditional therapeutic options are often limited. Through its research and development efforts, PAQ Therapeutics aims to provide new solutions for patients in need of advanced medical therapies.